drugset / Trial / NCT03511625

The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis

NCT03511625

RandomizedParallel-groupSingle-blindTreatment

Summary

Patients will be assigned to receive either Depo Medrol or Acthar treatment. A synovial biopsy, blood draws, synovial fluid aspiration, and physician assessments will be performed before and after initiating treatment.

Timeline

Start
2018-10-02
Primary completion
2020-02-26
Completion
2024-12-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Acthar Peptide 80 iu Subcutaneous
Comparator Methylprednisolone Other / unclassified 40 mg Intramuscular

Indications